Last reviewed · How we verify
Valsartant treatment
Valsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure.
Valsartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction left ventricular dysfunction.
At a glance
| Generic name | Valsartant treatment |
|---|---|
| Sponsor | University Hospital, Grenoble |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone-mediated sodium and water retention, resulting in reduced blood pressure and improved cardiac function.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction left ventricular dysfunction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartant treatment CI brief — competitive landscape report
- Valsartant treatment updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI